185 related articles for article (PubMed ID: 32575557)
21. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
[TBL] [Abstract][Full Text] [Related]
22. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
23. Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma.
Amengual JE; Clark-Garvey S; Kalac M; Scotto L; Marchi E; Neylon E; Johannet P; Wei Y; Zain J; O'Connor OA
Blood; 2013 Sep; 122(12):2104-13. PubMed ID: 23913470
[TBL] [Abstract][Full Text] [Related]
24. Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin.
Sun N; Wang CY; Sun YQ; Ruan YJ; Huang YY; Su T; Zhou XH; Huang H; Guo WJ; He MQ; Yao RX; Lin XJ
Biomed Pharmacother; 2018 Oct; 106():267-274. PubMed ID: 29966970
[TBL] [Abstract][Full Text] [Related]
25. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL.
Kalac M; Scotto L; Marchi E; Amengual J; Seshan VE; Bhagat G; Ulahannan N; Leshchenko VV; Temkin AM; Parekh S; Tycko B; O'Connor OA
Blood; 2011 Nov; 118(20):5506-16. PubMed ID: 21772049
[TBL] [Abstract][Full Text] [Related]
26. Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.
Sun K; Atoyan R; Borek MA; Dellarocca S; Samson ME; Ma AW; Xu GX; Patterson T; Tuck DP; Viner JL; Fattaey A; Wang J
Mol Cancer Ther; 2017 Feb; 16(2):285-299. PubMed ID: 27980108
[TBL] [Abstract][Full Text] [Related]
27. Genetics and diffuse large B-Cell lymphoma.
Niroula R; Butera J
R I Med J (2013); 2015 Nov; 98(11):23-6. PubMed ID: 26517251
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
29. Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy.
Gupta M; Han JJ; Stenson M; Wellik L; Witzig TE
Leukemia; 2012 Jun; 26(6):1356-64. PubMed ID: 22116549
[TBL] [Abstract][Full Text] [Related]
30. Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma.
Derenzini E; Agostinelli C; Imbrogno E; Iacobucci I; Casadei B; Brighenti E; Righi S; Fuligni F; Ghelli Luserna Di Rorà A; Ferrari A; Martinelli G; Pileri S; Zinzani PL
Oncotarget; 2015 Mar; 6(9):6553-69. PubMed ID: 25544753
[TBL] [Abstract][Full Text] [Related]
31. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
[TBL] [Abstract][Full Text] [Related]
32. Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells.
Cortiguera MG; García-Gaipo L; Wagner SD; León J; Batlle-López A; Delgado MD
Sci Rep; 2019 Nov; 9(1):16495. PubMed ID: 31712669
[TBL] [Abstract][Full Text] [Related]
33. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
[TBL] [Abstract][Full Text] [Related]
34. The Frequency of Double Expresser in Selected Cases of High Grade Diffuse Large B-Cell Lymphomas.
Naseem M; Asif M; Khadim MT; Ud-Din H; Jamal S; Shoaib I
Asian Pac J Cancer Prev; 2020 Apr; 21(4):1103-1107. PubMed ID: 32334477
[TBL] [Abstract][Full Text] [Related]
35. Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma.
Melchor J; Garcia-Lacarte M; Grijalba SC; Arnaiz-Leché A; Pascual M; Panizo C; Blanco O; Segura V; Novo FJ; Valero JG; Pérez-Galán P; Martinez-Climent JA; Roa S
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36854569
[TBL] [Abstract][Full Text] [Related]
36. Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms.
Nguyen T; Parker R; Zhang Y; Hawkins E; Kmieciak M; Craun W; Grant S
BMC Cancer; 2018 Nov; 18(1):1129. PubMed ID: 30445933
[TBL] [Abstract][Full Text] [Related]
37. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
[TBL] [Abstract][Full Text] [Related]
38. Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells.
Fernández-Rodríguez C; Salar A; Navarro A; Gimeno E; Pairet S; Camacho L; Ferraro M; Serrano S; Besses C; Bellosillo B; Sanchez-Gonzalez B
Leuk Lymphoma; 2016; 57(3):692-9. PubMed ID: 26084206
[TBL] [Abstract][Full Text] [Related]
39. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas.
Duan H; Heckman CA; Boxer LM
Mol Cell Biol; 2005 Mar; 25(5):1608-19. PubMed ID: 15713621
[TBL] [Abstract][Full Text] [Related]
40. Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl‑2 pathway.
Zhang H; Chi F; Qin K; Mu X; Wang L; Yang B; Wang Y; Bai M; Li Z; Su L; Yu B
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33649847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]